Literature DB >> 2526742

Human interleukin 6 and tumor necrosis factor alpha production studied at a single-cell level.

U Andersson1, T Matsuda.   

Abstract

Individual peripheral blood mononuclear cells, which produced interleukin 6 (IL 6) or tumor necrosis factor alpha, (TNF alpha), were studied by cytokine-specific polyclonal or monoclonal antibodies (mAb) and immunofluorescence technique with UV microscopy. Lipopolysaccharide (LPS) induced IL 6 as well as TNF alpha production in the majority of the monocytes, but not at all in lymphocytes. Approximately every second monocyte made TNF alpha in response to LPS within 0.5 h from start of the cultures, when no IL 6 or TNF alpha production occurred. The maximal number of TNF alpha-synthesizing monocytes was observed 1.5 h later and then rapidly declined. LPS stimulation led to optimal IL 6 production 3 h after initiation of the cultures, with 90% of the monocytes expressing intracellular IL 6. LPS-induced IL 6 synthesis started about 1 h after that of TNF alpha. Polyclonal T cell activation with staphylococcal enterotoxin A or anti-CD3 mAb induced a biphasic production pattern of IL 6 as well as TNF alpha. Early IL 6 synthesis, which peaked 6-8 h from start of the cultures, occurred exclusively in monocytes, while late IL 6 production at 48 h was restricted to a small fraction of lymphoid cells. T cell mitogen induced early TNF alpha production, which peaked at 6 h, took mainly place in monocytes and to a minor degree in CD4+ as well as CD8+ T cells. The majority of the TNF alpha-producing mononuclear cells at 24 h were of the CD4+ T cell lineage in the staphylococcal enterotoxin A- or anti-CD3 mAb-activated cultures. IL 6 as well as TNF alpha accumulated in the Golgi system, which resulted in a characteristic morphology of the staining, eliminating problems with evaluation of background signals.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526742     DOI: 10.1002/eji.1830190629

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

Review 1.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

2.  Human intravenous immunoglobulin modulates monokine production in vitro.

Authors:  J P Andersson; U G Andersson
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

Review 3.  Regulation of tumor necrosis factor production by monocyte-macrophages and lymphocytes.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

4.  Frequency and risk factors for liver disease following pancreatitis: A population-based cohort study.

Authors:  Shayal K Chand; Sayali A Pendharkar; Sakina H Bharmal; Adam S Bartlett; Stephen J Pandol; Maxim S Petrov
Journal:  Dig Liver Dis       Date:  2018-11-16       Impact factor: 4.088

5.  Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression.

Authors:  M Aguilar-Santelises; R Magnusson; S B Svenson; A Loftenius; B Andersson; H Mellstedt; M Jondal
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

6.  Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators.

Authors:  Bernd Bodenmiller; Eli R Zunder; Rachel Finck; Tiffany J Chen; Erica S Savig; Robert V Bruggner; Erin F Simonds; Sean C Bendall; Karen Sachs; Peter O Krutzik; Garry P Nolan
Journal:  Nat Biotechnol       Date:  2012-09       Impact factor: 54.908

7.  Abnormal TNF-alpha production in diabetes-prone BB rats: enhanced TNF-alpha expression and defective PGE2 feedback inhibition.

Authors:  H Rothe; C Ongören; S Martin; P Rösen; H Kolb
Journal:  Immunology       Date:  1994-03       Impact factor: 7.397

8.  Francisella tularensis-induced in vitro gamma interferon, tumor necrosis factor alpha, and interleukin 2 responses appear within 2 weeks of tularemia vaccination in human beings.

Authors:  R Karttunen; H M Surcel; G Andersson; H P Ekre; E Herva
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

9.  Contribution of non-Leishmania-specific immunity to resistance to Leishmania infection in humans.

Authors:  H O Akuffo; S F Britton
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

10.  Search for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein.

Authors:  A R Neurath; N Strick; P Sproul
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.